专家论坛

特发性肺纤维化与阻塞性睡眠呼吸暂停

展开
  • 山东大学齐鲁医院呼吸与危重症医学科,山东 济南 250012

收稿日期: 2021-03-07

  网络出版日期: 2022-07-26

本文引用格式

马德东, 赵恩琪, 浦英 . 特发性肺纤维化与阻塞性睡眠呼吸暂停[J]. 内科理论与实践, 2021 , 16(02) : 84 -87 . DOI: 10.16138/j.1673-6087.2021.02.004

参考文献

[1] Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study[J]. Lancet Respir Med, 2015, 3(4):310-318.
[2] 陈曦, 伍俊. 特发性肺纤维化的机制与治疗[J]. 生命的化学, 2020, 40(3): 329-336.
[3] Li D, Wang B, Liu Y, et al. Prevalence and impact of comorbid obstructive sleep apnoea in diffuse parenchymal lung diseases[J]. PLoS One, 2021, 16(2): e0246878.
[4] Mavroudi M, Papakosta D, Kontakiotis T, et al. Sleep disorders and health-related quality of life in patients with interstitial lung disease[J]. Sleep Breath, 2018, 22(2): 393-400.
[5] Pihtili A, Bingol Z, Kiyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease[J]. Sleep Breath, 2013, 17(4): 1281-1288.
[6] Zhang XL, Dai HP, Zhang H, et al. Obstructive sleep apnea in patients with fibrotic interstitial lung disease and COPD[J]. J Clin Sleep Med, 2019, 15(12): 1807-1815.
[7] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
[8] Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective[J]. Am J Respir Crit Care Med, 2002, 165(9): 1217-1239.
[9] Cardoso AV, Pereira N, Neves I, et al. Obstructive sleep apnoea in patients with fibrotic diffuse parenchymal lung disease-characterization and treatment compliance assessment[J]. Can J Respir Ther, 2018, 54(2): 35-40.
[10] Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis[J]. Chest, 2009, 136(3): 772-778.
[11] Şahin Duyar S, Uzel Şener M, Akıncı Özyürek B, et al. An integrated approach toward the clinical and polysomnographic characteristics of OSA accompanying IPF[J]. Turk Thorac J, 2020, 21(5): 334-339.
[12] Heinzer RC, Stanchina ML, Malhotra A, et al. Lung vo-lume and continuous positive airway pressure requirements in obstructive sleep apnea[J]. Am J Respir Crit Care Med, 2005, 172(1): 114-117.
[13] Sériès F, Cormier Y, Lampron N, et al. Increasing the functional residual capacity may reverse obstructive sleep apnea[J]. Sleep, 1988, 11(4): 349-353.
[14] Chrousos GA, Kattah JC, Beck RW, et al. Side effects of glucocorticoid treatment[J]. JAMA, 1993, 269(16): 2110-2112.
[15] Bosi M, Milioli G, Fanfulla F, et al. OSA and prolonged oxygen desaturation during sleep are strong predictors of poor outcome in IPF[J]. Lung, 2017, 195(5): 643-651.
[16] Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis[J]. J Clin Sleep Med, 2013, 9(6): 593-601.
[17] Mermigkis C, Mermigkis D, Varouchakis G, et al. CPAP treatment in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea-therapeutic difficulties and dilemmas[J]. Sleep Breath, 2012, 16(1): 1-3.
[18] da Rosa DP, Forgiarini LF, Baronio D, et al. Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver[J]. Mediators Inflamm, 2012, 2012: 879419.
[19] Weng T, Poth JM, Karmouty-Quintana H, et al. Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2014, 190(12): 1402-1412.
[20] Tiruvoipati R, Lewis D, Haji K, et al. High-flow nasal oxygen vs high-flow face mask: a randomized crossover trial in extubated patients[J]. J Crit Care, 2010, 25(3): 463-468.
[21] Tarraubella N, Sánchez-de-la-Torre M, Nadal N, et al. Management of obstructive sleep apnoea in a primary care vs sleep unit setting: a randomised controlled trial[J]. Thorax, 2018, 73(12): 1152-1160.
[22] Shepherd K, Hillman D, Holloway R, et al. Mechanisms of nocturnal gastroesophageal reflux events in obstructive sleep apnea[J]. Sleep Breath, 2011, 15(3): 561-570.
[23] Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis[J]. Sleep Breath, 2015, 19(1): 385-391.
[24] Kohler M, Bloch KE, Stradling JR. Pharmacological approaches to the treatment of obstructive sleep apnoea[J]. Expert Opin Investig Drugs, 2009, 18(5): 647-656.
[25] Canora A, Nicoletta C, Ghinassi G, et al. First description of the hyperpnea-hypopnea periodic breathing in patients with interstitial lung disease-obstructive sleep apnea: treatment implications in a real-life setting[J]. Int J Environ Res Public Health, 2019, 16(23): 4712.
[26] 姚娟娟. 无创呼吸机恒流模式的作用机制验证及舒适性评估[D]. 山东大学, 2020.
[27] Gille T, Didier M, Boubaya M, et al. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis[J]. Eur Respir J, 2017, 49(6): 1601934.
[28] 李庆云, 宋爱玲. 对特发性肺纤维化合并阻塞性睡眠呼吸暂停的新认识[J]. 中华医学杂志, 2019, 99(6): 416-418.
文章导航

/